Week of August 6, 2012: Boehringer, Servier, Xoma Form Biomanufacturing Agreement; Teva Canada Completes Sale of Mirabel (Quebec) Facility to Halo Pharmaceutical; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of August 6, 2012: Boehringer, Servier, Xoma Form Biomanufacturing Agreement; Teva Canada Completes Sale of Mirabel (Quebec) Facility to Halo Pharmaceutical; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Boehringer Ingelheim has entered into an agreement with Servier and its partner Xoma to transfer Xoma’s technology and process for the commercial manufacture of gevokizumab, Xoma’s novel interleukin 1-beta (IL-1β) allosteric modulating antibody for treating noninfectious uveitis. Upon completion of the transfer and the establishment of biological comparability, Boehringer Ingelheim is expected to produce gevokizumab at its facility in Biberach, Germany, for Servier’s commercial use. Additionally, Servier and Xoma will retain all rights to the development and commercialization of gevokizumab. Read More

Gilead Sciences, Mylan Laboratories, and the Indian pharmaceutical companies Ranbaxy Laboratories and Strides Arcolab, have agreed to collaborate on promoting access to generic versions of Gilead’s HIV medicine emtricitabine (FTC) in developing countries—including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine coformulated with other Gilead HIV medicines. Under the new agreements, Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce overall manufacturing costs. Read More

Teva Canada has completed the sale of Teva’s Mirabel (Montreal, Quebec) manufacturing facility to the CDMO Halo Pharmaceutical on July, 31, 2012. Under the terms of the sale, Teva Canada and Halo have established manufacturing agreements. Halo will continue to manufacture all products currently produced at the Mirabel site until the end of 2012. Afterwards, manufacturing operations will be transferred to Teva’s Stouffville, Ontario, facility. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here